Multiple studies have earlier demonstrated a clinical utility of CEA serum measurement in patients with gastric,37 pancreatic,38 non‐small cell lung,39 and breast cancer40 although most of these studies have not optimized patient selection by immunohistochemical CEA analysis of tumour tissue. This evidence concerns the gene CEACAM5 and neoplasm.